Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.

Real-world GLP-1 results usually undershoot the trials; this enormous digital-pharmacy cohort is notable for how little it does. Two findings stand out: consistent ordering cadence tracked with better outcomes, and clinically meaningful weight loss was frequently achieved at intermediate doses — relevant to the dose-escalation debates playing out in community forums. Caveats apply: self-reported weights, a self-selected paying population, and heavy attrition by month twelve, so the 12-month figure reflects the people who stayed the course.